GSK plc (GSK)
| Market Cap | 96.99B |
| Revenue (ttm) | 43.24B |
| Net Income (ttm) | 7.39B |
| Shares Out | 4.03B |
| EPS (ttm) | 1.79 |
| PE Ratio | 26.68 |
| Forward PE | 10.50 |
| Dividend | $1.68 (3.52%) |
| Ex-Dividend Date | Nov 14, 2025 |
| Volume | 8,200,937 |
| Open | 48.05 |
| Previous Close | 48.22 |
| Day's Range | 47.62 - 48.35 |
| 52-Week Range | 32.38 - 51.46 |
| Beta | 0.25 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Feb 4, 2026 |
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2024, GSK's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.
Financial numbers in GBP Financial StatementsNews
Forbion Announces Second Exit from Forbion Growth Fund III Following $2.2 Billion Acquisition of RAPT Therapeutics by GSK
NAARDEN, The Netherlands, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Forbion, a leading life sciences venture capital firm with deep roots in Europe, today announces that GSK (NYSE: GSK) has entered into a def...
GSK Announces Recipients of Linked by Lupus: Optimal Care Initiative Grants Nearing $1 Million
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) has announced the recipients of the Linked by Lupus: Optimal Care Initiative grant, awarding nearly $1 million to support national, state, and lo...
GSK to buy food allergy drug maker RAPT in $2.2bn deal
US-based biotech firm is developing treatment for allergies such as nuts, milk and eggs in children and adults
GSK announces $2.2 billion deal, targeting once-per-three-month food allergy drug
The growing scourge of food allergies drove U.K. heavyweight GSK to announce a $2.2 billion deal on Tuesday.
Alteogen Announces Exclusive License Agreement with Tesaro, a Subsidiary of GSK, for the Development of a Subcutaneous Formulation of Dostarlimab Enabled by Hybrozyme™ Technology
DAEJEON, South Korea, Jan. 20, 2026 /PRNewswire/ -- Alteogen Inc. (KOSDAQ: 196170) announced today that the company has entered into an exclusive license agreement with Tesaro, Inc., a subsidiary of G...
GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments
The drugmaker said it agreed to pay RAPT shareholders $58 per share, with $1.9 billion upfront investment in cash.
GSK to buy RAPT Therapeutics for $2.2 billion
GSK said on Tuesday that it would acquire U.S.-based RAPT Therapeutics for $2.2 billion.
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
GSK plc (GSK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
GSK plc (GSK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
GSK Still Has Room To Run Despite Vaccine Cyclicality
GSK's growth is increasingly specialty-led (HIV, RI&I, oncology), not just vaccines. ViiV's long-acting injectables also tap into durable demand. Recent launches/approvals like Blenrep in r/r myeloma ...
Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC)
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has entered into a clinical trial collaboration with GSK plc (“GSK”, LSE/NYSE: GSK) to evaluate ivonescimab...
AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty
AnaptysBio said on Thursday it filed a partial motion to dismiss a claim by GSK's oncology unit, which alleges the biotech breached their contract, escalating a legal dispute over royalties tied to sa...
GSK Licenses Noetik's AI Foundation Models in Anchor Partnership to Transform Cancer Therapeutic Research and Development
SAN FRANCISCO--(BUSINESS WIRE)-- #GSK--GSK licenses Noetik's AI foundation models in anchor partnership to transform cancer therapeutic research and development.
GSK/Ionis Partnered Investigational Drug Shows Strong Results In Large Hepatitis B Studies
Ionis Pharmaceuticals Inc. (NASDAQ: IONS) partner GSK Plc (NYSE: GSK) on Wednesday shared data from two pivotal Phase 3 studies, B-Well 1 and B-Well 2, of bepirovirsen, an investigational antisense ol...
GSK's chronic hepatitis B treatment meets main goal in key studies
GSK's experimental drug to treat chronic hepatitis B infection met the main goals in two closely watched studies, the drugmaker said on Wednesday, bringing the company a step closer to making a functi...
Exclusive: Drugmakers raise US prices on 350 medicines despite pressure from Trump
Drugmakers plan to raise U.S. prices on at least 350 branded medications including vaccines against COVID, RSV and shingles and blockbuster cancer treatment Ibrance, even as the Trump administration p...
Samsung Biologics to buy U.S. drug production facility from GSK for $280 mln
South Korea's Samsung Biologics said on Monday its U.S. unit is buying a U.S. drug production facility from GSK for $280 million.
Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK
Secures the company's first U.S.-based manufacturing site, strengthening and diversifying its global supply network Additional investments planned to expand the site's capacity (currently at 60,000 li...
Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay
The companies, including Bristol-Myers Squibb, GSK and Merck, would avoid potential U.S. tariffs in return.
Nine of the largest pharma companies ink deals with Trump to lower drug prices
Several of the largest U.S. and European-based drugmakers inked deals with President Donald Trump to voluntarily sell their medications for less, as his administration pushes to link the nation's drug...
GSK: 2026 Looks Good
GSK has surged ~46% YTD, far outpacing both the healthcare sector and S&P 500, which is notable considering the spectre of high US tariffs hanging over it. The recent US-UK pharmaceuticals deal, the c...
Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment of sev...
US FDA approves GSK's twice-yearly asthma drug
The U.S. Food and Drug Administration has approved GSK's add-on drug to treat asthma and a chronic inflammatory sinus condition, the drugmaker said on Tuesday, paving the way for a less frequently dos...
UK approves GSK's twice-yearly asthma drug
UK's health regulator on Monday approved GSK's twice-yearly drug for use as an add-on treatment for asthma in patients aged 12 and older, as well as for a chronic inflammatory sinus condition in adult...